EZH2 and hepatocellular carcinoma: To further investigate the influence of YAP on FGFR4 and EZH2 inhibitor treatment in vivo, we generated zebrafish HCC primary tumors with liver-specific overexpression of YAP1S87A (KRASG12V+/YAP1S87A+).